SG-BCC 2023丨肿瘤瞭望与您一起跨越山海,共同奔赴一场属于春天的约会
编者按:第18届St.Gallen国际乳腺病大会(SG-BCC 2023)于当地时间2023年4月15~18日在“世界音乐之都”维也纳举行,来自全球各地的乳腺病专家将在本次大会上讨论最前沿、最具争议的早期乳腺病诊治话题,形成每两年一更新的St.Gallen早期乳腺病国际专家共识。
本次大会,我们医学科学院肿瘤医院徐兵河院士、复旦大学附属肿瘤医院邵志敏教授、解放军总医院江泽飞教授将分别作为主题报告中Session 10、Session 7 和 Session9的专场领导与国外大咖一起主持相关环节。肿瘤瞭望团队也已奔赴会议现场,传递最新会议进展,实时关注会议动态,分享第一手资料。此外,肿瘤瞭望还将邀请业内专家针对本次会议上的重点内容以现场访谈、隔空对话、精彩述评等形式为大家献上精彩内容。
SG-BCC 2023大会上,您将看到以下内容
11个主题报告(Session 1-11)
Session 1:News in breast cancer care since SGBCC 2023(自2023年来乳腺病治疗进展的新闻)
Session 2:Genomics,Transcriptomics,ctDNA for disease monitoring and risk stratification(基因组学,转录组学以及ctDNA用于疾病监测和风险分层)
Session 3:Immunology in early breast cancer(早期乳腺病的免疫学研究)
Session 4:Hereditary Breast Cancer(遗传性乳腺病)
Session 5:The future treatment landscape in the adjuvant setting(未来辅助治疗的前景)
Session 6:Tailoring breast surgery and radiotherapy(乳房手术和放射治疗)
Session 7:Controversies in the treatment of the axilla(腋窝治疗的争议)
Session 8:Optimizing treatment in patients with HER2-positive breast cancer(优化HER2阳性乳腺病患者的治疗)
Session 9:Optimizing treatment in patients with triple negative breast cancer(优化三阴性乳腺病患者的治疗)
Session 10:Global Prespective on breast cancer treatment(乳腺病治疗全球展望)
Session 11:Optimizing treatment in patients with HR positive breast cancer(HR阳性乳腺病患者的优化治疗)
4个辩论环节(DebateⅠ-Ⅳ)
DebateⅠ:Early breast cancer:do we need chemotherapy in low genomic/high clinical risk(ER+/HER2-)?(低基因组/高临床风险(ER+/HER2-)早期乳腺病:患者是否需要化疗?)
DebateⅡ:Axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy(新辅助全身治疗后残余淋巴结患者腋窝清扫与腋窝放疗的比较)
DebateⅢ:If you achieve pCR after neoadjuvant,do you need adjuvant therapy?(如果新辅助治疗后达到pCR,是否需要进行辅助治疗?)
DebateⅣ:Surgery of the primary for stage IV disease(Ⅳ期乳腺病患者的初始手术治疗)
3个互动环节(Interactive SessionⅠ-Ⅲ)
Interactive SessionⅠ:How to avoid unnecessary mastectomies–a global discussion(如何避免不必要的乳房切除术——全球讨论)
Interactive SessionⅡ:Too big,too small?Too low,too high?Adjuvant choices when stage and biology do not align.(太大还是太小?太低还是太高?当分期和生物学不一致时的辅助治疗选择)
Interactive SessionⅢ:Controversies and uncertainties in axillary management(腋窝治疗的争议和不确定性)
2个专题讲座(Special lectureⅠ-Ⅱ)
Special lectureⅠ
The future of innovation:Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs?(Sara Tolaney,USA)(创新的未来:为什么我们要在那些不太可能负担得起创新药物的地方进行临床试验?)
Special lectureⅡ
Pushing the boundaries for cure–extending early BC to oligometastatic?(David Cameron,UK)(推动治疗的边界——将早期BC扩展到寡转移?)
3场SGBCC Academy
SGBCC Academy
Chair:Emiel Rutgers(Netherlands)
Co-Chair:Sara Brucker(Germany)
Discussants:Stefan Aebi(Switzerland),Meteb Al-Foheidi(KSA),Zefei Jiang(China),Toru Watanabe(Japan)
SGBCC Academy
Chair:Fatima Cardoso(Portugal)
Co-Chair:Carlos Barrios(Brazil)
Discussants:Jonas Bergh(Sweden)
SGBCC Academy
Chair:Elzbieta Senkus-Konefka(Poland)
Co-Chair:Miguel Martin(Spain)
Discussants:Chiun-Sheng Huang(Taiwan),Gerd Fastner(Austria)
SGBCC Academy特色主题如下,敬请关注!
2023年圣加伦国际乳腺病共识小组成员名单
圣加伦国际乳腺病共识小组成员中有四位来自我们的专家(排名不分先后):徐兵河、邵志敏、江泽飞、黄俊升(我们台),具体名单如下。